Back
  1. Home
  2. Profile of Mare Sabbe (ULiège)
Profil

Sabbe Mare

GIGA

See author's contact details
Main Referenced Co-authors
Louis, Renaud  (2)
Schleich, Florence  (2)
Bougard, Nicolas  (1)
Donneau, Anne-Françoise  (1)
Gerday, Sara  (1)
Main Referenced Keywords
Antibodies, Monoclonal, Humanized (1); Antibodies, Monoclonal, Humanized/pharmacology (1); Antibodies, Monoclonal, Humanized/therapeutic use (1); Asthma (1); Asthma/drug therapy (1);
Main Referenced Disciplines
General & internal medicine (2)

Publications (total 2)

The most downloaded
45 downloads
Schleich, F., SABBE, M., Moermans, C., & Louis, R. (January 2024). Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère. Revue Médicale de Liège, 79 (1), 60 - 64. https://hdl.handle.net/2268/313409

The most cited

1 citations (Scopus®)

Schleich, F., SABBE, M., Moermans, C., & Louis, R. (January 2024). Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère. Revue Médicale de Liège, 79 (1), 60 - 64. https://hdl.handle.net/2268/313409

Zahraei, H. N., Schleich, F., Louis, G., Gerday, S., SABBE, M., Bougard, N., GUISSARD, F., PAULUS, V., Henket, M., Pétré, B., Donneau, A.-F., & Louis, R. (2024). Evidence for two clusters among non-eosinophilic asthmatics. Annals of Allergy, Asthma and Immunology. doi:10.1016/j.anai.2024.03.012
Peer Reviewed verified by ORBi

Schleich, F., SABBE, M., Moermans, C., & Louis, R. (January 2024). Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère. Revue Médicale de Liège, 79 (1), 60 - 64.
Editorial Reviewed verified by ORBi

Contact ORBi